532321 Overzicht aandelen Zydus Lifesciences Limited houdt zich bezig met onderzoek, ontwikkeling, productie, marketing, distributie en verkoop van farmaceutische producten in India, de Verenigde Staten en internationaal. Meer informatie
Beloningen Risicoanalyse Alle risicocontroles bekijken Leg je gedachten, links en bedrijfsverhaal vast
Zydus Lifesciences Limited Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Zydus Lifesciences Historische aandelenkoersen Huidige aandelenkoers ₹1,004.05 52 Week Hoogtepunt ₹1,323.90 52 Week Laag ₹685.85 Bèta 0.47 1 maand verandering 1.80% 3 maanden verandering -5.77% 1 Jaar Verandering 42.68% 3 jaar verandering 127.08% 5 jaar verandering 273.11% Verandering sinds IPO 15,507.17%
Recent nieuws en updates
Zydus Lifesciences Limited Appoints Vikram Shukla as a President-Parenteral Operations Jan 03
Zydus Lifesciences Limited Receives Final Approval from USFDA for Lidocaine and Prilocaine Cream USP, 2.5%/2.5% Dec 19
Second quarter 2025 earnings: EPS misses analyst expectations Nov 13
Zydus Lifesciences Limited to Report Q2, 2025 Results on Nov 12, 2024 Oct 31
Zydus Lifesciences Limited Receives in Principle Acceptability from World Health Organization for Zyvac Tcv Oct 23
Zydus Lifesciences Limited Receives Final Approval from USFDA for Fludrocortisone Acetate Tablets USP, 0.1 Mg Oct 18 Meer updates bekijken
Zydus Lifesciences Limited Appoints Vikram Shukla as a President-Parenteral Operations Jan 03
Zydus Lifesciences Limited Receives Final Approval from USFDA for Lidocaine and Prilocaine Cream USP, 2.5%/2.5% Dec 19
Second quarter 2025 earnings: EPS misses analyst expectations Nov 13
Zydus Lifesciences Limited to Report Q2, 2025 Results on Nov 12, 2024 Oct 31
Zydus Lifesciences Limited Receives in Principle Acceptability from World Health Organization for Zyvac Tcv Oct 23
Zydus Lifesciences Limited Receives Final Approval from USFDA for Fludrocortisone Acetate Tablets USP, 0.1 Mg Oct 18
Zydus Lifesciences Limited and ICMR Initiate A Phase 2 Proof-Of-Concept Trial of Desidustat in Patients with Sickle Cell Disease Oct 15
Zydus Lifesciences Limited Receives Final Approval from USFDA for Paliperidone Extended-Release Tablets Oct 10 Zydus Receives Tentative Approval from USFDA for Enzalutamide Tablets, 40 Mg and 80 Mg Oct 02
Price target increased by 10% to ₹1,170 Aug 12 Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended on March 31, 2024
Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration to Market Valsartan Tablets USP, 40 Mg, 80 Mg, 160 Mg and 320 Mg (USRLD: Diovan® Tablets) Jul 23
Zydus Lifesciences Limited Receives Approval from COFEPRIS of Mexico to Market Bhava Jul 22
Upcoming dividend of ₹3.00 per share Jul 19
Zydus Lifesciences Limited to Report Q1, 2025 Results on Aug 09, 2024 Jul 18
Full year 2024 earnings: EPS and revenues exceed analyst expectations Jul 16
Zydus Receives Tentative Approval from Usfda for Azilsartan Medoxomil Tablets, 40 Mg and 80 Mg Jul 04
Dividend reduced to ₹3.00 May 24
Price target increased by 9.2% to ₹925 May 21
Zydus Lifesciences Limited, Annual General Meeting, Aug 09, 2024 May 19
Full year 2024 earnings: EPS and revenues exceed analyst expectations May 18
Zydus Lifesciences Limited Proposes Final Dividend for the Financial Year Ended on March 31, 2024, Payable on or After August 13, 2024 May 18
Zydus Lifesciences Limited Announces Completion of Enrolment for EPICS IIITM Phase 2B/3 Trial Evaluating Saroglitazar Mg in Treatment of Primary Biliary Cholangitis May 11
Zydus Lifesciences Limited Receives Final Approval from USFDA for Dapsone Gel, 7.5% May 10
Bayer Pharmaceuticals Pvt. Ltd. agreed to acquire the remaining 24.99998% stake in Bayer Zydus Pharma Private Limited for INR 2.82 billion. May 03 Zydus Lifesciences Limited Launches Mirabegron Extended-Release Tablets in the U.S
Insider recently sold ₹833k worth of stock Mar 26
Price target increased by 9.3% to ₹753 Feb 12
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Feb 10 Zydus Receives Tentative Approval from the USFDA for Dexamethasone Tablets USP, 1 mg
Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration to Manufacture and Market Dexamethasone Tablets USP, 2 Mg Feb 09
Zydus Lifesciences Launches RexigoTM, the Oral Once-A-Day Pill for Advanced Prostate Cancer Patients in India Jan 30
Zydus Lifesciences Limited Receives Final Approval from the USFDA for Gabapentin Tablets (Once-Daily), 300 Mg and 600 Mg Jan 25
Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration for Pimavanserin Capsules, 34 Mg and Pimavanserin Tablets,10 Mg Jan 19 Zydus Lifesciences Limited Zydus Receives Approval from USFDA to Initiate Phase II Clinical Trial of ZYIL1 in Patients with Parkinson's Disease
Zydus Lifesciences Limited Receives Final Approval from the USFDA for Cyclophosphamide Capsules USP, 25 Mg and 50 Mg Dec 14
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 09
Zydus Lifesciences Initiates Phase II Clinical Trial of ZYIL1 Oct 27
Zydus Lifesciences Limited Receives USFDA Approval for ZITUVIO™ to Treat Adult Patients with Type 2 Diabetes Mellitus Oct 21
Zydus Lifesciences Limited Appoints Mr. Punit Patel as President and CEO to Lead Its Business Operations in North America Oct 17
Zydus Receives Final Approval from the USFDA for Clindamycin Phosphate Gel USP, 1% Sep 21
Zydus Receives Final Approval from the USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 Mcg/35 Mcg Per Day Sep 16
Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration for Zinc Sulfate Injection USP, 10 mg/10 ml (3 mg/L) Pharmacy Bulk Package Vials Aug 25
Price target increased by 14% to ₹627 Aug 14
Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended on March 31, 2023 Aug 12
Zydus Lifesciences Limited (NSEI:ZYDUSLIFE) completed the acquisition of Active pharmaceutical ingredients arm of Watson Pharma from Watson Pharma. Aug 09
Zydus Lifesciences Limited Announces Resignation of Rashmin Shah as President-Special Projects Aug 04
Upcoming dividend of ₹6.00 per share at 1.0% yield Jul 21
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Jul 19 Zydus Lifesciences Limited to Report Q3, 2024 Results on Feb 14, 2024
Zydus Lifesciences Limited Receives Final Approval from the USFDA for Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg Jul 06 Zydus Lifesciences Limited Receives Final Approval from the Usfda for Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 Mg and 40 Mg
Price target increased by 7.6% to ₹536 May 21 Zydus Lifesciences Limited, Annual General Meeting, Aug 11, 2023
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind May 19
Zydus Lifesciences Limited, Annual General Meeting, Aug 11, 2023 May 19
Zydus Group Reportedly Looks to Sell Cliantha Research May 05
Zydus Lifesciences Limited Receives Final Approval from the USFDA for Sirolimus Tablets, 1 Mg and 2 Mg Feb 18
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Feb 05
Zydus Lifesciences Limited Receives Final Approval from the USFDA for Febuxostat Tablets Jan 11
Zydus Lifesciences Limited Receives Two Final Approvals from the USFDA for Silodosin Capsules and Pregabalin Capsules Dec 11
Zydus Lifesciences Limited Receives Final Approval from United States Food and Drug Administration to Market Topiramate Extended-Release Capsules Dec 03
Zydus Lifesciences Limited (NSEI:ZYDUSLIFE) entered into a Business Transfer Agreement to acquire Active pharmaceutical ingredients arm of Watson Pharma from Watson Pharma for approximately INR 470 million. Nov 30
Zydus Lifesciences Limited Receives Final Approval from the USFDA for Famotidine Injection Nov 24
Zydus Lifesciences Limited Gets Exclusive Marketing Rights for CanAssist Breast Nov 16
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 16
Insufficient new directors Nov 16
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 13
Zydus Lifesciences Limited Receives Final Approval from the USFDA for Bisoprolol Fumarate and Hydrochlorothiazide Tablets Nov 10
Zydus Lifesciences Limited Receives Final Approval from the USFDA for Acetaminophen Injection Oct 30
Zydus Lifesciences Limited Receives Final Approval from the USFDA for Micafungin for Injection Oct 28
Zydus Lifesciences Limited Receives Final Approval from the USFDA for Ketorolac Tromethamine Tablets Oct 23
Investor sentiment improved over the past week Oct 04
Zydus Lifesciences Limited Receives Final Approval from the USFDA for Lenalidomide Capsules 5 Mg, 10 Mg, 15 Mg and 25 Mg Sep 14
Zydus Lifesciences Limited Receives Final Approval and 180 Days Shared Exclusivity from the USFDA for Cariprazine Capsules Sep 13
Zydus Lifesciences Ltd. Achieves Positive Proof-of-Concept in its Phase 2 Clinical Study of ZYIL1, in Patients with CAPS Sep 08
Zydus Lifesciences Ltd. Announces Phase IV DREAM-CKD Trial to Generate Real World Evidence of Desidustat in Patients with Chronic Kidney Disease Induced Anemia Aug 30
Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended March 31, 2022 Aug 11
Zydus Receives Final Approval from the USFDA for Ivermectin Cream Aug 06
Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration for Bisoprolol Fumarate Tablets Jul 27
Upcoming dividend of ₹2.50 per share Jul 21 Zydus Lifesciences Limited to Report Q3, 2023 Results on Feb 14, 2023
Now 21% undervalued Jul 12
Zydus Lifesciences Ltd. Receives Final Approval from the USFDA for Empagliflozin and Metformin Hydrochloride Tablets Jul 12
Zydus Lifesciences Limited Launches Molecule Sitagliptin in India Under the Brand Names Sitaglyn ® and Siglyn Jul 09 Rendement voor aandeelhouders 532321 IN Pharmaceuticals IN Markt 7D 2.9% -4.0% -4.5% 1Y 42.7% 29.0% 11.1%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: 532321 overtrof de Indian Pharmaceuticals industrie, die het afgelopen jaar een rendement 29 % opleverde.
Rendement versus markt: 532321 overtrof de Indian markt, die het afgelopen jaar een rendement opleverde van 11.1 %.
Prijsvolatiliteit Is 532321's price volatile compared to industry and market? 532321 volatility 532321 Average Weekly Movement 3.1% Pharmaceuticals Industry Average Movement 6.0% Market Average Movement 6.1% 10% most volatile stocks in IN Market 9.0% 10% least volatile stocks in IN Market 4.1%
Stabiele aandelenkoers: 532321 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de Indian markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 3% ) van 532321 is het afgelopen jaar stabiel geweest.
Over het bedrijf Opgericht Werknemers CEO Website 1952 26,921 Sharvil Patel zyduslife.com
Zydus Lifesciences Limited houdt zich bezig met onderzoek, ontwikkeling, productie, marketing, distributie en verkoop van farmaceutische producten in India, de Verenigde Staten en internationaal. Het is actief in twee segmenten: Farmaceutische Producten en Consumentenproducten. Het biedt afgewerkte doseringsformuleringen voor mensen, zoals generieke geneesmiddelen; merkgenerieke geneesmiddelen; speciale formuleringen, waaronder biosimilars en vaccins; actieve farmaceutische ingrediënten; welzijnsproducten voor de consument; producten voor diergezondheid; en producten in de therapeutische gebieden pijnbestrijding, neurologie, stofwisselingsstoornissen en leverziekten.
Meer tonen Zydus Lifesciences Limited Samenvatting Hoe verhouden de winst en inkomsten van Zydus Lifesciences zich tot de beurswaarde? 532321 fundamentele statistieken Marktkapitalisatie ₹1.01t Inkomsten(TTM ) ₹42.78b Inkomsten(TTM ) ₹214.84b
23.6x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) 532321 resultatenrekening (TTM ) Inkomsten ₹214.84b Kosten van inkomsten ₹63.03b Brutowinst ₹151.81b Overige uitgaven ₹109.03b Inkomsten ₹42.78b
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) 42.51 Brutomarge 70.66% Nettowinstmarge 19.91% Schuld/Eigen Vermogen Verhouding 0.6%
Hoe presteerde 532321 op de lange termijn?
Bekijk historische prestaties en vergelijking Dividenden
0.3% Huidig dividendrendement
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2025/01/10 05:00 Aandelenkoers aan het einde van de dag 2025/01/10 00:00 Inkomsten 2024/09/30 Jaarlijkse inkomsten 2024/03/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .
Bronnen van analisten Zydus Lifesciences Limited wordt gevolgd door 69 analisten. 29 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Nitin Bhasin Ambit Capital Sriraam Rathi Anand Rathi Shares and Stock Brokers Limited null null Anand Rathi Shares and Stock Brokers Limited
Toon 66 meer analisten 
